NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus

Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two...

Full description

Saved in:
Bibliographic Details
Main Authors: Hans D. Brightbill, Eric Suto, Nicole Blaquiere, Nandhini Ramamoorthi, Swathi Sujatha-Bhaskar, Emily B. Gogol, Georgette M. Castanedo, Benjamin T. Jackson, Youngsu C. Kwon, Susan Haller, Justin Lesch, Karin Bents, Christine Everett, Pawan Bir Kohli, Sandra Linge, Laura Christian, Kathy Barrett, Allan Jaochico, Leonid M. Berezhkovskiy, Peter W. Fan, Zora Modrusan, Kelli Veliz, Michael J. Townsend, Jason DeVoss, Adam R. Johnson, Robert Godemann, Wyne P. Lee, Cary D. Austin, Brent S. McKenzie, Jason A. Hackney, James J. Crawford, Steven T. Staben, Moulay H. Alaoui Ismaili, Lawren C. Wu, Nico Ghilardi
Format: article
Language:EN
Published: Nature Portfolio 2018
Subjects:
Science
Q
Online Access:https://doaj.org/article/c1b21708fc0a4c58b4c58242d9d32c50
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/c1b21708fc0a4c58b4c58242d9d32c50

Similar Items